Profile
Barbara M.
Finn held several positions in regulatory affairs and quality assurance at various pharmaceutical companies, including Neurocrine Biosciences, Novartis Corp., and Sonexa Therapeutics.
She also worked as a manager at Quintiles, Inc. and as a principal at RAP Group, Inc. Currently, she is the VP of Regulatory Affairs and Quality Assurance at Otonomy, Inc. Finn received her undergraduate degree from the College of Saint Elizabeth.
Former positions of Barbara M. Finn
| Companies | Position | End |
|---|---|---|
| OTONOMY | General Counsel | 28/02/2023 |
RAP Group, Inc.
 RAP Group, Inc. Specialty StoresRetail Trade Part of ZAP, RAP Group, Inc. is a company that acquires and sells repossessed automobiles. The company is based in Fulton, CA. The company was founded by Steven M. Schneider. RAP Group was acquired by ZAP from Advanced Info Service Public Co. Ltd. on March 15, 2002. | Corporate Officer/Principal | - |
Novartis Corp.
 Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Quintiles, Inc. (California)
 Quintiles, Inc. (California) Medical/Nursing ServicesHealth Services Quintiles, Inc. provides therapeutic services. It offers medical services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. The company was founded in 1982 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | - |
Sonexa Therapeutics, Inc.
 Sonexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sonexa Therapeutics, Inc. developed drug treatments for Alzheimer's disease (AD) and related disorders. Its lead compound, ST101 had demonstrated both the cognitive benefits of currently marketed AD treatments along with significant disease modifying effects. The company was founded in January 2008 and was headquartered in San Diego, CA. | General Counsel | - |
Training of Barbara M. Finn
| Saint Elizabeth University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| NEUROCRINE BIOSCIENCES, INC. | Health Technology |
| Private companies | 5 |
|---|---|
Quintiles, Inc. (California)
Quintiles, Inc. (California) Medical/Nursing ServicesHealth Services Quintiles, Inc. provides therapeutic services. It offers medical services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. The company was founded in 1982 and is headquartered in San Francisco, CA. | Health Services |
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Health Technology |
RAP Group, Inc.
RAP Group, Inc. Specialty StoresRetail Trade Part of ZAP, RAP Group, Inc. is a company that acquires and sells repossessed automobiles. The company is based in Fulton, CA. The company was founded by Steven M. Schneider. RAP Group was acquired by ZAP from Advanced Info Service Public Co. Ltd. on March 15, 2002. | Retail Trade |
Sonexa Therapeutics, Inc.
Sonexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sonexa Therapeutics, Inc. developed drug treatments for Alzheimer's disease (AD) and related disorders. Its lead compound, ST101 had demonstrated both the cognitive benefits of currently marketed AD treatments along with significant disease modifying effects. The company was founded in January 2008 and was headquartered in San Diego, CA. | Health Technology |
Otonomy, Inc.
 Otonomy, Inc. BiotechnologyHealth Technology Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. | Health Technology |
- Stock Market
- Insiders
- Barbara M. Finn
